Opinion

Video

Real-World Data Surrounding Sequencing Strategies for Refractory mCRC

Author(s):

Aparna R. Parikh, MD,Marwan G. Fakih, MD

Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.

Related Videos
Peter Forsyth, MD
Richard Kim, MD, Moffitt Cancer Center
Tiago Biachi, MD, PhD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
Cancer / Image credit: Cornflakesei – stock.adobe.com
December 2nd 2024

Moffitt Study Shows How Cancer Cell Death May Harm the Immune System and Promote Tumor Growth

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Nicole Lamanna, MD, associate clinical professor, medicine, Hematologic Malignancies Section, Hematology/Oncology Division, Columbia University Herberg Irving Comprehensive Cancer Center
November 25th 2024

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

The Microbiome and Colon Cancer | Image Credit: © Anatomy Insider - stock.adobe.com
November 25th 2024

The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality

Joleen Hubbard, MD, medical oncologist, Allina Health Cancer Institute
October 31st 2024

SUNLIGHT QOL Data Show Positive Outcomes With Trifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD

Sebastian Kaulitzki – stock.adobe.com
November 15th 2024

CHMP Recommends Approval of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC

Colorectal Cancer
November 15th 2024

GRANITE Plus ICIs and Bevacizumab/Chemo Shows Improved PFS Trend in MSS mCRC